A bottle labeled "CBD oil" sitting in a wellness store or on a marketplace listing can legally contain THC. Not a trace by accident, but by design, and by federal definition. If you're buying a cannabis product for your child and assuming "CBD" means "no THC," that assumption is the gap where accidental exposure happens.

The Legal Definition That Confuses Everyone

The 2018 Farm Bill defines hemp, and by extension legal CBD, as cannabis containing no more than 0.3% THC by dry weight. That's not zero. A product can be entirely compliant with federal law and still deliver measurable THC with every dose, especially in a product marketed for daily use.

This is where the label terms matter. CBD isolate contains only CBD, with THC removed through additional processing. Broad-spectrum contains multiple cannabis compounds but has THC removed or reduced to non-detectable levels. Full-spectrum contains the complete range of compounds naturally found in the plant, including THC up to that 0.3% legal limit. Companies market full-spectrum products around the "entourage effect," the theory that cannabis compounds work better together than isolated. That claim has some early research support for adults. It also means a full-spectrum product is the one most likely to produce a positive drug test or a noticeable effect in a small child, where even a legal, small dose of THC is a larger relative dose than it would be for an adult.

Why Mislabeling Is a Real Risk, Not a Hypothetical

The FDA has repeatedly tested commercial CBD products and found a gap between label and contents. A widely cited 2017 study in JAMA tested 84 products purchased online and found that over a fifth contained detectable THC despite labels that didn't disclose it. The FDA has also issued warning letters to CBD companies for exactly this kind of labeling failure.

For an adult, an unexpected small dose of THC might mean feeling unexpectedly foggy for an afternoon. For a child, particularly one already on medication for epilepsy or anxiety, an undisclosed dose of a psychoactive compound is a different kind of problem: unpredictable behavioral effects, drug interactions no one is tracking, and a positive result on a drug screen that a parent can't explain because they didn't know THC was in the product to begin with.

How to Verify What's in the Bottle

A certificate of analysis (COA) from an independent, third-party lab is the only reliable way to know what a product contains. A legitimate COA shows:

Cannabinoid content, listing CBD, THC, and other compounds as a percentage or milligram amount, tested by a lab with no financial stake in the product's sales.

Batch-specific testing, meaning the COA matches the specific batch number on your product, not a generic testing report the company runs once and reuses across every batch it sells.

Contaminant screening, covering pesticides, heavy metals, and residual solvents, which matters because hemp is a bioaccumulator that pulls contaminants from soil more readily than many other crops.

If a company doesn't publish a COA, or publishes one that doesn't match your product's batch number, don't buy that product for a child.

What to Choose Based on What You're Trying to Avoid

If your priority is eliminating THC exposure entirely, an isolate product is the only category that reliably delivers that, and even then, verify it with a COA rather than trusting the label alone. Broad-spectrum products should be non-detectable for THC, but "should be" is doing real work in that sentence, and testing varies by manufacturer. Full-spectrum products are the category most likely to contain measurable THC, and are the ones parents should scrutinize hardest before giving to a child, regardless of entourage effect marketing.

For families managing epilepsy specifically, this distinction matters even more. Epidiolex, the only FDA-approved CBD medication, is a purified formulation with THC removed, tested and dosed with precision that no over-the-counter product replicates. If your child needs predictable dosing for a seizure disorder, that regulatory gap between a pharmaceutical and a supplement is the reason to talk to a neurologist about Epidiolex before trying a retail product, a distinction covered in more depth in the research on CBD safety for children with epilepsy.

Reading a Label Before You Buy

Look for the word "isolate" or "broad-spectrum" if avoiding THC is the goal. Treat "full-spectrum" as a flag to check the COA before purchase, not after. Confirm the COA is batch-matched and less than a year old. If your child takes any prescription medication, ask the pharmacist about interactions before adding any cannabis product, THC-containing or not. And if a listing doesn't include a COA at all, buy elsewhere, or don't buy the product for your child.

The broader question of whether CBD helps with your child's specific symptoms is a separate one, covered in the general guide to CBD marketing versus the evidence. This is the narrower question underneath it: whatever you decide about trying CBD, know precisely what compound you're giving your child, and confirm it with paperwork, not a label.